查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016897

移植市場：2026-2032年全球市場預測（按器官、產品類型、捐贈者、手術和最終用戶分類）

Transplantation Market by Organ Type, Product Type, Donor Type, Procedure Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，器官移植市場價值為 118.7 億美元，預計到 2026 年將成長至 128.4 億美元，年複合成長率為 9.20%，到 2032 年將達到 219.9 億美元。

主要市場統計數據
基準年 2025 118.7億美元
預計年份：2026年 128.4億美元
預測年份 2032 219.9億美元
複合年成長率 (%) 9.20%

簡要介紹臨床創新、保守技術和程序變革如何重塑移植醫學的交付系統和商業性重點。

移植醫學正處於一個關鍵的轉折點，外科技術、生物技術和器官保存方法的進步正在重新定義臨床應用的可能性。灌注和保存技術的最新創新，以及免疫抑制療法的改進，延長了移植的適應症窗口期，並使更複雜的手術成為可能。同時，捐贈者管理方式的改變以及微創和機器人手術的興起，正在改變醫療服務路徑，迫使醫院系統和供應商重新思考物流、採購和培訓結構。

外科手術方法、器官保存科學和基於結果的報銷模式的轉變如何全面改變移植醫學生態系統。

在移植醫學領域，臨床實務、技術應用和政策環境正經歷變革性的變化，所有這些都在重新定義競爭優勢。在臨床上，為了減少手術全期併發症並加速患者康復，傳統開放性手術正明顯轉向機器人輔助手術和腹腔鏡手術。伴隨這一趨勢，精準管理免疫抑制療法日益重要，新的藥物和聯合治療旨在抑制排斥反應的同時，減輕長期副作用。

評估 2025 年美國關稅調整對移植供應鏈和採購韌性的營運和策略影響。

2025年美國關稅政策的變化給整個植入物供應鏈帶來了壓力，影響了籌資策略、供應商關係和成本結構。某些進口零件和原料關稅的提高增加了醫療設備、耗材和植入製造商的接收成本，迫使採購團隊重新評估供應商多元化和離岸外包方案。由於醫療機構需要在控制成本和確保時間敏感型手術的連續性之間取得平衡，這些趨勢對庫存管理實踐和前置作業時間緩衝產生了連鎖反應。

將器官特定臨床需求、產品層級、捐贈途徑、治療方案和醫療保健環境聯繫起來的綜合細分智慧，有助於策略優先排序。

為了整體情況移植醫學，必須整合來自五個細分觀點的信息，從而全面掌握臨床實踐、產品、捐贈者、手術流程和最終用戶的多樣性。以器官類型分析，可以發現心臟、腸道、腎臟、肝臟、肺臟和胰臟移植在臨床重點和醫療設備需求方面有顯著差異。例如，器官特異性的保存需求和術後監測方案會影響產品需求和臨床工作流程。從產品類型角度來看，此生態系涵蓋耗材，例如導管、移植物和縫合線；醫療設備，例如監測設備、灌注設備和保存液；植入植入，包括人工器官和血管移植物；以及藥品，包括抗增殖劑、鈣調Calcineurin抑制劑、皮質類固醇和mTOR抑制劑。這種產品層級結構突顯了哪些領域的漸進式創新和供應限制會對營運產生最大的影響。

區域戰略觀點反映了美洲、歐洲、中東和非洲以及亞太地區的臨床能力、法規結構和採購標準有何不同。

區域趨勢塑造了移植醫學的整體情況，包括技術應用軌跡、監管節點和夥伴關係機會。在美洲，臨床領先的中心往往率先採用先進的器官保存系統和機器人技術，而公共和私人支付方的器官獲取模式各不相同，這影響著採購週期和合約結構。歐洲和中東及非洲的情況則較為複雜，監管協調、基礎設施差異以及器官共用協議的跨國合作既帶來了機遇，也帶來了營運上的複雜性。在該地區，多中心註冊登記和指南的協調統一被反覆強調，以期改善治療效果。

醫療設備製造商、生物製藥公司和專業創新者之間的競爭與合作動態正在塑造移植相關產品和服務交付的未來。

移植領域的競爭動態並非由單一的領導者主導，而是由醫療設備製造商、製藥公司、醫院和利基創新者組成的生態系統互動所決定。成熟的醫療設備公司繼續利用其規模、監管經驗和分銷網路，將監測系統、灌注平台和植入式技術商業化。生物製藥公司則專注於下一代免疫抑制劑和輔助性治療，以提高移植器官的存活率和患者的生活品質。同時，小規模、高度專業化的公司和大學衍生企業正在推動諸如保存化學、生物工程移植材料和人工器官開發等領域的顛覆性創新。

為高階主管提供切實可行的策略措施，以加強供應韌性、加速臨床引入，並協調移植領域的價值交付和報銷。

移植領域的領導者應採取重點策略，以增強韌性、加速臨床應用並協調相關人員的獎勵。首先，他們應優先考慮供應鏈多元化，並為關鍵零件建立在地化生產能力，以降低關稅波動和單一來源依賴的風險。其次，他們應投資於臨床醫生培訓項目，並建立臨床證據，以證明移植能夠改善患者預後並降低總治療成本，同時促進與支付者進行更具建設性的對話。第三，他們應設計綜合服務包，將醫療設備、保存液、臨床訓練和術後監測結合，以簡化採購流程，並為醫院和專科診所帶來可衡量的價值。

我們高度透明的研究途徑，結合文獻綜述、專家訪談和資料檢驗，在臨床和商業領域產生檢驗且可操作的見解。

本研究整合了定性和定量信息，結合系統性文獻綜述、針對性專家訪談和跨領域資料三角驗證，建構了移植生態系統的整體情況。調查方法首先對同行評審的臨床研究、監管申報文件和指南更新進行了全面檢驗，以建立臨床和科學基礎。此外，還對移植外科醫生、器官捐贈者、醫院管理人員和行業高管進行了結構化訪談，以揭示營運細節、未滿足的需求以及推廣應用的障礙。

最終得出切實可行的結論，重點闡述了決定移植領域臨床實施、營運韌性和商業性成功的共同促進因素。

總之，移植醫學正處於一個轉折點，技術進步、不斷演變的程序規範和政策框架在此交匯融合，共同開闢新的臨床和商業性路徑。器官特異性臨床挑戰、涵蓋耗材、醫療設備、植入和藥品等多元化產品以及捐贈者和手術環境的多樣性，都凸顯了差異化策略的必要性。投資於穩健供應鏈、實證實踐、與臨床醫生合作以及整合服務模式的機構，將更有能力將創新轉化為永續的臨床影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依器官類型分類的移植市場

  • 心
  • 腸子
  • 腎
  • 肝
  • 肺
  • 胰臟

第9章 移植市場：依產品類型分類

  • 消耗品
    • 導管
    • 接枝
    • 縫合線
  • 醫療設備
    • 監控設備
    • 灌注裝置
    • 防腐液
  • 植入
    • 人工器官
    • 血管移植
  • 製藥
    • 抗增殖劑
    • Calcineurin抑制劑
    • 皮質類固醇
    • mTOR抑制劑

第10章 移植市場：依供體類型分類

  • 已故捐贈者
  • 活體捐贈者

第11章 器官移植市場：依手術類型分類

  • 腹腔鏡
  • 剖腹手術
  • 機器人手術

第12章：移植市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章 移植市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 移植市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 移植市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國器官移植市場

第17章：中國器官移植市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 21st Century Medicine
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bio-Rad Laboratories, Inc.
  • BiolifeSolutions, Inc.
  • Bristol-Myers Squibb Company
  • CHIESI Farmaceutici SpA
  • Dr. Franz Kohler Chemie GmbH
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Johnson & Johnson
  • Medtronic PLC
  • Merck KGaA
  • Novartis AG
  • Organ Recovery Systems, Inc.
  • Organovo, Inc.
  • OrganOx Limited
  • Pfizer Inc.
  • Plexision, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-031685195793

The Transplantation Market was valued at USD 11.87 billion in 2025 and is projected to grow to USD 12.84 billion in 2026, with a CAGR of 9.20%, reaching USD 21.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.87 billion
Estimated Year [2026] USD 12.84 billion
Forecast Year [2032] USD 21.99 billion
CAGR (%) 9.20%

A concise primer on how clinical innovations, preservation technologies, and procedural shifts are reshaping transplantation care delivery and commercial priorities

Transplantation medicine is at a pivotal juncture, driven by advances in surgical techniques, biotechnologies, and organ preservation methods that are redefining clinical possibilities. Recent innovations in perfusion and preservation, together with enhanced immunosuppressive regimens, have extended viable windows for transplantation and enabled more complex procedures. Concurrently, shifts in donor management and the rise of minimally invasive and robotic approaches are altering care pathways, requiring hospital systems and suppliers to rethink logistics, procurement, and training frameworks.

This report synthesizes clinical, technological, regulatory, and payer-facing dynamics to present an integrated executive perspective. It emphasizes how product portfolios-from consumables such as catheters, grafts, and sutures to devices including monitoring and perfusion systems, and implants like artificial organs and vascular grafts-interact with evolving procedural choices and donor profiles. The narrative connects operational realities in ambulatory surgical centers, hospitals, and specialty clinics with broader trends in clinical outcomes and patient access. Ultimately, this introduction frames transplantation as a sector with intersecting clinical complexity and commercial opportunity, setting the stage for the deeper analyses that follow.

How shifts in surgical approaches, organ preservation science, and outcome-focused reimbursement models are collectively transforming the transplantation ecosystem

The transplantation landscape is experiencing transformative shifts across clinical practice, technology adoption, and policy environments that together recalibrate competitive advantage. Clinically, there is a clear movement from traditional open procedures to robotic-assisted and laparoscopic techniques, driven by the desire to reduce perioperative morbidity and accelerate recovery. This trend is accompanied by a growing emphasis on precision management of immunosuppression, where newer agents and combination strategies aim to reduce rejection while mitigating long-term adverse effects.

Technological shifts are equally consequential. The maturation of organ perfusion and preservation solutions has improved organ viability, while advances in monitoring devices enable more granular perioperative and post-transplant management. At the same time, implants-ranging from advanced vascular grafts to nascent artificial organ prototypes-are progressing from concept to clinical feasibility, prompting re-examination of care pathways. Regulatory and reimbursement environments are adapting to these innovations, with payers and health systems increasingly rewarding demonstrable improvements in patient outcomes and total cost of care. Taken together, these forces are not incremental; they are reshaping procurement priorities, clinical team competencies, and long-term strategic roadmaps across providers and suppliers.

Assessment of the operational and strategic consequences of United States tariff adjustments in 2025 on transplantation supply chains and procurement resilience

Tariff policy changes in the United States in 2025 introduced discrete pressures across the transplantation supply chain, influencing sourcing strategies, supplier relationships, and cost structures. Increased duties on certain imported components and raw materials have raised landed costs for manufacturers of devices, consumables, and implants, prompting procurement teams to revisit supplier diversification and nearshoring options. These dynamics have had ripple effects on inventory practices and lead-time buffers, as healthcare providers balance cost containment with the imperative to maintain continuity of care for time-sensitive procedures.

In response, many manufacturers accelerated efforts to localize critical manufacturing steps or to qualify alternative sources that reduce exposure to tariff volatility. Clinical and supply chain leaders adapted by strengthening demand forecasting and by negotiating service-level agreements that emphasize resilience. Additionally, there has been renewed interest in value-based contracting and bundled payment structures that can absorb episodic cost pressures while aligning incentives across stakeholders. While regulatory compliance and quality assurance remain paramount, the tariffs catalyzed a broader reassessment of supply resilience and strategic procurement that will influence supplier selection and partnership models going forward.

Integrated segmentation intelligence that connects organ-specific clinical needs, product hierarchies, donor pathways, procedural choices, and care settings to inform strategic prioritization

A nuanced understanding of the transplantation landscape requires integrating insights across five segmentation lenses that together capture clinical, product, donor, procedural, and end-user variability. When analyzed by organ type, clinical priorities and device needs differ substantially between heart, intestine, kidney, liver, lung, and pancreas transplantation; for example, organ-specific preservation requirements and post-operative monitoring protocols shape product demand and clinical workflows. From a product type perspective, the ecosystem spans consumables such as catheters, grafts, and sutures; devices including monitoring devices, perfusion devices, and preservation solutions; implants covering artificial organs and vascular grafts; and pharmaceuticals comprising antiproliferative agents, calcineurin inhibitors, corticosteroids, and mTOR inhibitors. This product hierarchy underscores where incremental innovation and supply constraints exert the greatest operational impact.

Donor type segmentation divides practice between deceased donor and living donor pathways, each presenting distinct logistical and ethical considerations that affect procurement timelines, consent processes, and preoperative optimization. Procedure type segmentation highlights the differing resource profiles and training demands associated with laparoscopic, open, and robotic procedures, which in turn alter capital planning and perioperative staffing models. Finally, end-user segmentation across ambulatory surgical centers, hospitals, and specialty clinics demonstrates how care setting influences adoption speed for new technologies, procurement cycles, and integration with existing clinical networks. Synthesizing these lenses allows stakeholders to tailor strategies that reflect clinical nuance and operational realities rather than one-size-fits-all assumptions.

Regional strategic perspectives reflecting how clinical capacity, regulatory frameworks, and procurement norms vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape adoption trajectories, regulatory touchpoints, and partnership opportunities across the transplantation landscape. In the Americas, clinical centers of excellence often drive early implementation of advanced preservation systems and robotic techniques, while procurement models vary between public and private payers, influencing purchasing cycles and contracting structures. Europe, the Middle East & Africa present a heterogeneous mosaic in which regulatory alignment, infrastructure disparities, and cross-border collaboration on organ sharing protocols create both opportunities and operational complexity; this region frequently emphasizes multicenter registries and guideline harmonization to elevate outcomes.

Asia-Pacific is characterized by rapid investment in surgical capacity, growing clinical research activity, and increasing local manufacturing capabilities that can reshape global supply relationships. Across all regions, reimbursement frameworks, workforce training pipelines, and national policies on donor registries influence how quickly new technologies move from approval to routine use. Consequently, commercial strategies that succeed in one geography often require recalibration to accommodate differences in procurement norms, regulatory expectations, and clinical practice patterns in another, making regionally informed roadmaps essential for international players.

Competitive and partnership dynamics across device makers, biopharmaceutical firms, and specialist innovators that are shaping the future of transplantation product and service offerings

Competitive dynamics in transplantation are defined less by a single dominant player and more by ecosystem orchestration involving device manufacturers, pharmaceutical firms, hospitals, and niche innovators. Established medical device companies continue to leverage scale, regulatory experience, and distribution networks to commercialize monitoring systems, perfusion platforms, and implantable technologies. Biopharmaceutical organizations focus on next-generation immunosuppressive regimens and adjunct therapies that improve graft longevity and patient quality of life. Meanwhile, smaller, specialized firms and academic spinouts contribute disruptive innovations in preservation chemistry, bioengineered graft materials, and artificial organ development.

Partnership strategies are increasingly central to competitive advantage; collaborations between clinical centers and industry accelerate real-world evidence generation and support payer engagement. Mergers and acquisitions are often driven by the desire to integrate complementary capabilities, such as combining device platforms with software-enabled monitoring or adding proprietary preservation solutions to a broader surgical portfolio. To differentiate, companies are investing in services that reduce clinical friction, including training programs, comprehensive maintenance, and digital tools for perioperative coordination. Overall, success favors organizations that align clinical value propositions with operational support and durable reimbursement strategies.

Action-centered strategic measures for executives to fortify supply resilience, accelerate clinical adoption, and align reimbursement with value delivery in transplantation

Leaders in the transplantation sector should pursue focused strategies that strengthen resilience, accelerate clinical adoption, and align stakeholder incentives. First, prioritize supply chain diversification and qualification of local manufacturing capacity for mission-critical components to mitigate exposure to tariff volatility and single-source dependencies. Second, invest in clinician training programs and clinical evidence generation that demonstrate improved patient outcomes and reduced total episode costs, facilitating more constructive payer conversations. Third, design bundled service offerings that combine devices, preservation solutions, clinical training, and post-operative monitoring to simplify procurement and deliver measurable value to hospitals and specialty clinics.

In parallel, executives should pursue strategic collaborations with high-performing transplant centers to co-develop and validate new technologies, supporting faster uptake and more persuasive value narratives. Embrace digital tools that enhance perioperative coordination and remote monitoring, as these can reduce complications and enable efficient use of limited specialist resources. Finally, maintain active engagement with regulators and reimbursement bodies to shape policy frameworks that recognize the clinical and economic benefits of advanced preservation technologies and integrated care models. By executing these recommendations, organizations can convert clinical innovation into sustainable commercial advantage.

Transparent research approach blending literature review, expert interviews, and data triangulation to produce validated, actionable insights across clinical and commercial domains

This research integrates qualitative and quantitative inputs to construct a holistic view of the transplantation ecosystem, combining systematic literature review, targeted expert interviews, and cross-functional data triangulation. The methodology began with an exhaustive review of peer-reviewed clinical studies, regulatory submissions, and guideline updates to establish the clinical and scientific foundation. This was complemented by structured interviews with transplant surgeons, procurement leaders, hospital administrators, and industry executives to capture operational nuances, unmet needs, and adoption barriers.

Secondary sources such as device registries, clinical trial repositories, and public policy documents were analyzed to validate trends and to map technology readiness levels. Triangulation techniques were applied to reconcile discrepancies across sources, and sensitivity checks ensured that operational interpretations were robust across geographies and care settings. Finally, segmentation frameworks were applied to align insights to organ type, product type, donor pathway, procedure type, and end-user context, enabling the development of actionable recommendations suited to different stakeholder priorities. Throughout, adherence to ethical research practices and data integrity standards guided evidence selection and synthesis.

Synthesis of actionable conclusions highlighting the converging drivers that will determine clinical adoption, operational resilience, and commercial success in transplantation

In conclusion, transplantation is poised at an inflection point where technological advances, shifting procedural norms, and evolving policy frameworks converge to create new clinical and commercial pathways. The interplay between organ-specific clinical challenges, a diverse product landscape encompassing consumables, devices, implants, and pharmaceuticals, and variable donor and procedural contexts underscores the need for differentiated strategies. Organizations that invest in resilient supply chains, evidence generation, clinician engagement, and integrated service models will be better positioned to translate innovation into sustained clinical impact.

Moving forward, success will depend on the ability to navigate regional regulatory heterogeneity, respond to procurement and reimbursement dynamics, and build partnerships that accelerate real-world adoption. By focusing on patient-centric outcomes, operational efficiency, and collaborative value delivery, stakeholders can contribute to a transplantation ecosystem that improves access, outcomes, and long-term graft survival while creating sustainable pathways for commercial growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplantation Market, by Organ Type

  • 8.1. Heart
  • 8.2. Intestine
  • 8.3. Kidney
  • 8.4. Liver
  • 8.5. Lung
  • 8.6. Pancreas

9. Transplantation Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Catheters
    • 9.1.2. Grafts
    • 9.1.3. Sutures
  • 9.2. Devices
    • 9.2.1. Monitoring Devices
    • 9.2.2. Perfusion Devices
    • 9.2.3. Preservation Solutions
  • 9.3. Implants
    • 9.3.1. Artificial Organs
    • 9.3.2. Vascular Grafts
  • 9.4. Pharmaceuticals
    • 9.4.1. Antiproliferative Agents
    • 9.4.2. Calcineurin Inhibitors
    • 9.4.3. Corticosteroids
    • 9.4.4. Mtor Inhibitors

10. Transplantation Market, by Donor Type

  • 10.1. Deceased Donor
  • 10.2. Living Donor

11. Transplantation Market, by Procedure Type

  • 11.1. Laparoscopic
  • 11.2. Open
  • 11.3. Robotic

12. Transplantation Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transplantation Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transplantation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transplantation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Transplantation Market

17. China Transplantation Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 21st Century Medicine
  • 18.6. AbbVie Inc.
  • 18.7. Astellas Pharma Inc.
  • 18.8. Baxter International Inc.
  • 18.9. Bio-Rad Laboratories, Inc.
  • 18.10. BiolifeSolutions, Inc.
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. CHIESI Farmaceutici S.p.A.
  • 18.13. Dr. Franz Kohler Chemie GmbH
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Illumina, Inc.
  • 18.16. Johnson & Johnson
  • 18.17. Medtronic PLC
  • 18.18. Merck KGaA
  • 18.19. Novartis AG
  • 18.20. Organ Recovery Systems, Inc.
  • 18.21. Organovo, Inc.
  • 18.22. OrganOx Limited
  • 18.23. Pfizer Inc.
  • 18.24. Plexision, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANTATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSPLANTATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANTATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 197. GCC TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. GCC TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 227. G7 TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. G7 TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 237. NATO TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. NATO TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)